Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies
An increasing number of newer targeted oncologic therapies approved for clinical use can cause drug-related pneumonitis. Drug-related pneumonitis can be difficult to diagnose and requires a high index of suspicion. This review serves as an update to a prior review in this journal about pneumonitis w...
| 發表在: | Journal of Immunotherapy and Precision Oncology |
|---|---|
| Main Authors: | , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Innovative Healthcare Institute
2024-11-01
|
| 主題: | |
| 在線閱讀: | https://jipo.org/doi/pdf/10.36401/JIPO-24-12 |
| 總結: | An increasing number of newer targeted oncologic therapies approved for clinical use can cause drug-related pneumonitis. Drug-related pneumonitis can be difficult to diagnose and requires a high index of suspicion. This review serves as an update to a prior review in this journal about pneumonitis with precision oncology therapies. In this review, we focus on the incidence, timing of onset, and imaging patterns of pneumonitis associated with a number of newly approved precision oncologic agents, with a particular focus on new antibody-drug conjugate therapies. |
|---|---|
| ISSN: | 2666-2345 2590-017X |